|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||187.78 - 195.20|
|52 Week Range||144.07 - 195.81|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||75.86|
|Earnings Date||Jan 29, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||202.45|
The Boston-based company, which makes treatments for cystic fibrosis and infectious diseases, said in a statement that Ian Smith, its chief operating officer and interim chief financial officer, had been terminated, effective immediately. Vertex said the dismissal was unrelated to the company’s financial performance, and the decision was reached following an investigation by outside law firm Wilmer Cutler Pickering Hale & Dorr LLP. “We are deeply committed to our culture of diversity, inclusion and respect, and we insist that all of our employees, regardless of their seniority, live our values and adhere to our code of conduct,” Jeffrey Leiden, Vertex’s chief executive, said in the statement.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith’s termination is the result of personal behavior that violated Vertex’s Code of Conduct and values and is unrelated to the Company’s financial and business performance. The Company and the Board made this determination following a prompt and comprehensive investigation conducted with the assistance of independent external counsel, WilmerHale.
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals Incorporated (VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with that in patients aged 6 years and older.
The major stock indexes ended a four-day win streak but losses were minor, while Netflix showed new signs of rising from its deep slump.
Vertex Pharmaceuticals is the IBD Stock Of The Day as the leading biotech stock broke out in above-average volume The biotech is a leader in treatments for cystic fibrosis, a lung disease.
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.
Jeffrey Leiden has been the CEO of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) since 2012. First, this article will compare CEO compensation with compensation at other large companies. After that, we will Read More...
Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday ## CRISPR’s performance On January 7, CRISPR Therapeutics (CRSP) stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4. On January 4, CRISPR Therapeutics stock rose ~8.03% to $30.27 from its previous close of $28.02 on January 3. On January 7, CRISPR closed ~54% up from its 52-week low of $22.22 on December 21, 2018. The company hit its 52-week high of $73.90 on May 24, 2018. ## Reason for the stock price hike On January 4, the FDA granted a fast track designation to CRISPR Therapeutics and Vertex Pharmaceuticals’ (VRTX) CTX001 for the treatment of individuals with sickle cell disease. The FDA’s fast track designation will help Vertex and CRISPR with several benefits, including the more frequent scheduling of meetings and communication with the FDA. The fast track designation will also allow the companies to file for the accelerated approval or priority review of their biologics license applications. Right now, CRISPR Therapeutics and Vertex Pharmaceuticals are enrolling patients in Phase 1 and Phase 2 trials for the evaluation of CTX001 for the treatment of individuals with sickle cell disease. ## Analysts’ recommendations Of the 11 analysts tracking CRISPR Therapeutics in January, one has recommended a “strong buy,” while six have recommended “buys” on the stock. Three analysts have recommended “holds,” while one has recommended a “sell” on the stock. On January 7, CRISPR Therapeutics had a consensus 12-month target price of $63.72, which represents a potential ~86.21% return on investment over the next 12 months.
CEO Jeff Leiden told the audience at the J.P. Morgan Healthcare Conference exactly what the biotech plans to achieve this year.
Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Earnings trends In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year. In the third quarter of 2018, the company reported net income and EPS of -$76.4 million and -$1.15, respectively, compared to -$47.7 million and -$0.78 in the third quarter of 2017. Wall Street analysts anticipate that in the fourth quarter of 2018, Sarepta Therapeutics will report net income and EPS of -$63.26 million and -$0.95, respectively. Analysts also estimate that the company will report net income and EPS of -$274.73 million and -$4.16, respectively, in fiscal 2018. Wall Street analysts estimate that BioMarin Pharmaceuticals (BMRN), Nektar Therapeutics (NKTR), and Vertex Pharmaceuticals (VRTX), Sarepta Therapeutics’ peers in the biopharmaceuticals market, will report EPS of around -$0.62, $3.88, and $2.88, respectively, in fiscal 2018. ## Recent developments On January 2, 2019, Sarepta Therapeutics entered a long-term strategic relationship with Aldevron. Aldevron is one of the leading producers of custom proteins, nucleic acids, and antibodies for use in the biotech industry. As per the terms of the agreement, Aldevron will supply plasmid DNA for the fulfillment of Sarepta Therapeutics’ requirements in its gene therapy clinical trials and commercial purposes. Aldevron will specifically supply GMP-grade plasmid for Sarepta Therapeutics’ micro-dystrophin Duchenne muscular dystrophy (or DMD) and Limb-girdle muscular dystrophy (or LGMD) gene therapy programs. As per the terms of the agreement, Aldevron will also supply plasmid for Sarepta Therapeutics’ future gene therapy programs. The agreement is expected to help Sarepta Therapeutics with sufficient plasmid for research and commercial purposes. Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 2 - How Is Sarepta Therapeutics Positioned in January?
Who Is Eyeing Sarepta Therapeutics Now? (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million. In the third quarter of 2018, the company’s revenue grew ~71% YoY to $78.5 million from $46.0 million. Wall Street analysts estimate that Sarepta Therapeutics will generate revenues of $85.8 million in the fourth quarter of 2018. Analysts also estimate that the company’s net revenue in fiscal 2018 will be around $301.1 million, which represents ~49.9% YoY growth. In the third quarter of 2018, Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN), Sarepta Therapeutics’ peers in the biopharmaceuticals market, reported revenues of $27.8 million, $783.9 million, and $391.7 million, respectively, which represents a ~81.9% YoY decline, a ~42.04% YoY increase, and a ~17.23% YoY increase. Wall Street analysts estimate that Nektar Therapeutics (NKTR), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceuticals (BMRN) will generate revenues of $1.2 billion, $3.0 billion, and $1.5 billion, respectively, which represents ~289%, ~37.41%, and ~15% YoY growth. ## Expense trends In the first nine months of 2018, Sarepta Therapeutics’ cost of sales excluding amortization of in-licensed rights amounted to $21.1 million compared to $3.8 million in the same period the prior year. In the first nine months of 2018, Sarepta Therapeutics reported R&D (research and development) and SG&A (selling, general, and administrative) expenses of $255.6 million and $143.5 million, respectively, compared to $122.3 million and $90.5 million in the same period the prior year. Wall Street analysts estimate that Sarepta Therapeutics will report cost of sales, SG&A, and R&D expenses of $30.2 million, $190.88 million and $317.02 million, respectively, in fiscal 2018. Continue to Next Part Browse this series on Market Realist: * Part 1 - Sarepta Therapeutics Stock Rose 96% in 2018 * Part 3 - A Look at Sarepta Therapeutics’ Recent Developments
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.
Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.